


Management of Acute Agitation in Pediatric Patients  
 Katie Krausz, Pharm.D.  
 PGY1 Pharmacy Resident at St. Louis Children’s Hospital



Manuel et. al. J Am Coll Emerg Physicians Open. 2022 June 20; 3(3): e12766. 5

| Neurotransmitter | Imbalance in Agitation | Causing...  |
|------------------|------------------------|---|
| Dopamine         | Excess                 | Poor impulse control<br>Increased aggression<br>Mania |
| Norepinephrine   | Excess                 | Hyperactivity<br>Panic attacks<br>Restlessness        |
| Serotonin        | Deficient              | Increased anxiety<br>Impulsive aggression             |
| GABA             | Deficient              | Hallucinations<br>Disorganized behavior               |

**BETA Consensus Document**


- A. Goals of Therapy
  - a. Collaborative practice
  - b. Treat based off etiology
    - i. Example: If a patient is hungry, find the patient something to eat.
  - c. Non-pharm management first
    - i. Verbal de-escalation is key in management of acute agitation

” q q äk äãsí k s| gsi k| ẽã flNB ” NÛäg~äk ± ß

|                |  |                                   |
|----------------|--|-----------------------------------|
|                | / ñá käs{ k  é^zqä~è á<br>Ω fl ü † £ ü æ | +~  éã~z5 ä~è á<br>Ω fl ü ß ° ß æ |
| * ^ãk z  k     | ç ç ü                                    | ç ¶ ü                             |
| 7 êkã k  ẽ~  π | ü ° §                                    | ç ¶ §                             |

πá fl · ü Æü ü

J r óãsg^zMkãèã^s| éQäk i èk ẽ~ ” q q äk äãs~|



/ ñá käs{ k| é^zqä~è á fl î käf ^zi k kãg^z^ẽs~| q ä~è á

+kz- rã^ k éBzHã-| éJ äógr Æü†† ” á ä~ü°üü ãüüÆ ü¶

# Recommended Medications


- Antipsychotics**
  - Haloperidol
  - Chlorpromazine
  - Olanzapine
  - Ziprasidone
  - Quetiapine
  - Risperidone
- Benzodiazepines**
  - Lorazepam
  - Midazolam
- Antihistamines**
  - Diphenhydramine

Gerson et. al. Western J of Emer Medicine. 2019; 20(2): 409-41820

| Medication     | Mechanism of Action   |
|----------------|---|
| Haloperidol    | Antagonizes dopamine-2  |
| Ziprasidone    | Antagonizes dopamine-2, serotonin, alpha-1 and histamine-1                |
| Olanzapine     | Antagonizes dopamine-1, serotonin, alpha-1, histamine-1, and muscarinic-1 |
| Chlorpromazine | Antagonizes dopamine-2, histamine-1, and muscarinic-1                     |
| Risperidone    | Antagonizes dopamine-2, serotonin, and alpha-1                            |
| Quetiapine     | Antagonizes dopamine-2, serotonin, and histamine-1                        |

Haloperidol (+lorazepam):

| Methods  | Primary Objective                                  | Results  | Conclusions   |
|--|--|--|---|
| Double-blind, prospective, randomized study in adults in ED (n=98)<br><br>IM haloperidol 5mg, IM lorazepam 2mg or combination of therapies | Change from baseline in ABS scores and BPRS scores | Combination vs. Lorazepam vs. Haloperidol:<br>p = 0.04 | Combination of lorazepam and haloperidol lower ABS scores more than monotherapy of haloperidol or lorazepam |



## Ziprasidone:

| Methods  | Primary objective   | Results   | Conclusion   |
|--|---|---|--|
| Retrospective, nonrandom study in adolescents (n = 52) | Compare efficacy and safety of IM ziprasidone to IM haloperidol and lorazepam | <b>Restraint duration:</b><br>Z: 55 min, H+L: 65 min<br>p=NS<br><b>Rescue medications:</b><br>Z: 2/28, H+L: 1/24<br>p=0.6 | Ziprasidone is equally effective as the combination of haloperidol and lorazepam |

## Olanzapine:

| Methods   | Primary Objective  | Results   | Conclusions  |
|---|--|---|--|
| Retrospective chart review of patients less than 18 years treated with IM ziprasidone or olanzapine | Provide information on dosing, response, safety and tolerability | <b>Number of doses of emergency medication:</b> O: 11 vs. Z: 21; p=0.009<br><b>Number of aggressive episodes:</b> O: 9 vs. Z: 14; p=0.497 | IM ziprasidone and IM olanzapine are equally effective |

## Chlorpromazine:

| Methods  | Primary Objective  | Results  | Conclusion  |
|--|--|--|---|
| Retrospective chart review in patients <18 years (n=145) | Compare effectiveness and safety of IM chlorpromazine vs. IM olanzapine in treating aggression in pediatrics | Pre-IM BARS score:<br>C: 6.26; O: 6.29<br>Post-IM BARS score:<br>C: 3.21; O: 2.71<br>p=0.004 | Olanzapine lowers BARS score more than chlorpromazine, but both are efficacious |

## Risperidone and Quetiapine

| Methods  | Primary Objective  | Results   | Conclusions  |
|--|--|-----------|--|
| Prospective, rater-blinded study comparing risperidone, olanzapine, quetiapine and haloperidol | Change in baseline in MOAS total score and the MOAS categories of aggression | See below | No difference between risperidone, quetiapine and olanzapine |


| MOAS Total Score | Risperidone | Olanzapine | Quetiapine | Haloperidol | P value |
|------------------|-------------|------------|------------|-------------|---------|
| Baseline         | 7.52        | 6.79       | 7.95       | 9.54        |         |
| Endpoint         | 0.26        | 0.50       | 0.05       | 0.18        | 0.551   |

## Side effects of Antipsychotics:

| Adverse Event | Risperidone | Olanzapine | Quetiapine | Haloperidol | P value |
|---------------|-------------|------------|------------|-------------|---------|
| Abnormal gait | 7.4%        | 8.3%       | 4.6%       | 7.1%        | 0.964   |
| Dizziness     | 3.7%        | 12.5%      | 18%        | 3.6%        | 0.204   |
| EPS           | 7.4%        | 0          | 0          | 21.4%       | 0.012   |
| Headache      | 3.7%        | 8.3%       | 4.6%       | 7.1%        | 0.888   |
| Hypotension   | 7.4%        | 17%        | 14%        | 14%         | 0.780   |
| Somnolence    | 11.1%       | 21%        | 7%         | 18%         | 0.338   |

## Diphenhydramine:

| Patients                             | Method   | Results   | Conclusion  |
|--------------------------------------|--|-----------|---|
| Male patients (n=21) aged 5-13 years | Double blind, placebo-controlled trial<br>IM Diphenhydramine vs. placebo | See below | Diphenhydramine is no better than placebo for acute agitation |



## Benzodiazepines:

| Methods  | Methods   | Results   |   | Conclusions   |
|--|---|---|---|---|
| Randomized, prospective, double-blind controlled trial in adults (n=111) | Compare efficacy in sedation between lorazepam, midazolam and haloperidol | Mean time to sedation:<br>L: 32.2 min<br>H: 28.3 min<br>M: 18.3 min<br>p < 0.05 | Mean time to arousal:<br>L: 217.2 min<br>H: 126.5min<br>M: 81.9 min<br>P < 0.05 | Midazolam sedates patients the quickest and wears off first.<br>All medications are effective sedation medications. |

## Medication formulations:

| Medication      | IM  | Tablet | Liquid | ODT |
|-----------------|-----|--------|--------|-----|
| Diphenhydramine | Yes | Yes    | Yes    |     |
| Haloperidol     | Yes | Yes    | Yes    |     |
| Chlorpromazine  | Yes | Yes    | Yes    |     |
| Olanzapine      | Yes | Yes    |        | Yes |
| Quetiapine      |     | Yes    |        |     |
| Risperidone     |     | Yes    |        | Yes |
| Lorazepam       | Yes | Yes    | Yes    |     |
| Midazolam       | Yes |        | Yes    |     |

**Recommendations:****I always recommend:**

| Medication                                | Patient population   | With ____ agitation       | Because...   |
|---|--|---------------------------|--|
| PO Olanzapine, Risperidone, or Quetiapine | In patients with a known psychiatric illness and able/willing to take PO | Mild, moderate, or severe | <ul style="list-style-type: none"> <li>Targets the neurotransmitters involved with psychiatric illness and acute agitation</li> <li>Proven efficacy</li> <li>Improved side effect profile</li> </ul> |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| IM Olanzapine      | In patients with a known psychiatric illness and unable/unwilling to take PO | Moderate-severe | <ul style="list-style-type: none"> <li>• Targets neurotransmitters involved with psychiatric illness and acute agitation</li> <li>• Proven efficacy</li> <li>• Improved side effect profile</li> </ul> |
| PO Diphenhydramine | In patients with an unknown etiology for agitation able to take PO           | Mild            | <ul style="list-style-type: none"> <li>• Does not target neurotransmitters involved with psychiatric illness or acute agitation</li> <li>• Benign side effect profile</li> </ul>                       |

### I sometimes recommend...

| Medication                       | Patient Population                           | In a situation where...  | Because...   |
|----------------------------------|--|--|--|
| PO or IM Chlorpromazine          | In patients with a known psychiatric illness | The patient is unresponsive to olanzapine, risperidone or quetiapine             | <ul style="list-style-type: none"> <li>• Targets neurotransmitters involved with psychiatric illness and acute agitation</li> <li>• Proven efficacy</li> <li>• Worse side effect profile compared to olanzapine, risperidone and quetiapine</li> </ul> |
| PO or IM Haloperidol + Lorazepam | In patients with a psychiatric illness       | The patient is Moderately-severely agitated and unresponsive to all other agents | <ul style="list-style-type: none"> <li>• Only targets one neurotransmitter involved with psychiatric illness and acute agitation</li> <li>• Risk of dystonic reactions in pediatric patients</li> </ul>  |

|                             |   |   |   |
|-----------------------------|---|---|---|
| PO or IM<br>Benzodiazepines | In patients with agitation due to an unknown etiology | The patient is moderately-severely agitated | <ul style="list-style-type: none"><li>• Does not target neurotransmitters involved with psychiatric illness or acute agitation</li><li>• Too sedating</li></ul> |
|-----------------------------|---|---|---|